Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2022 17:16 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

SIOUX FALLS, S.D., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...
November 21, 2022 08:14 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

SIOUX FALLS, S.D., Nov. 21, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
November 15, 2022 08:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results

SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
November 08, 2022 08:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022

SIOUX FALLS, S.D., Nov. 08, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
November 03, 2022 09:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference

SIOUX FALLS, S.D., Nov. 03, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
October 27, 2022 08:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions

SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform...
September 28, 2022 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron

SIOUX FALLS, S.D., Sept. 28, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
September 23, 2022 08:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants

SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
August 10, 2022 08:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results

SIOUX FALLS, S.D., Aug. 10, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
August 09, 2022 16:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right